Skip to content

Global Partners

US · GLP #2946 by market cap Listed 1970
42.13 -1.13 -2.61%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Leading Novo Nordisk! China's first oral GLP-1 weight-loss drug has been approved and production has already begun ahead of schedule.
    cls.cn · 2026/11/12
  • Rating change
    TR | OpenAI - 4o Maintains Global Partners(GLP.US) With Hold Rating, Maintains Target Price $53
    Market Newswire · 2025/8/11
  • Rating change
    Neutral Outlook on Magnum Ice Cream Co.: Soft Demand, Margin Pressure, and GLP-1 Risks Cap Near-Term Upside
    TipRanks · 2026/2/12
  • U.S. Regulators Warn GLP-1 Drugs Carry Possible Rare Blindness Risk -- WSJ
    WSJ · 2026/11/9
  • Company notice
    ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF TWO PHASE I STUDIES INU.S. FOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, AN AMYLIN RECEPTOR PEPTIDE AGONIST, ANDASC36_35FDC ONCE-MONTHLY INJECTION, A CO-FORMULATION OFASC36 AND GLP-1R/G
    HKEX · 2026/8/10
  • Multiple GLP-1 injectables have been included in the National Reimbursement Drug List (NRDL) for the first time, including products from Pfizer and Innovent Biologics, for the treatment of type 2 diabetes in adults.
    Sina Tech · 2026/11/14
  • Company notice
    ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS SUBMITS TWO IND APPLICATIONS TO THE U.S. FDAFOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, A PEPTIDE AMYLIN RECEPTOR AGONIST,AND ASC36_35 FDC ONCE-MONTHLY INJECTION,A CO-FORMULATION OF ASC36 PLUS PEPTIDE GLP-1R
    HKEX · 2026/7/6
  • Company notice
    GLP J-REIT: Aug. 2026 (29th) FISCAL PERIOD
    JPX · 2026/10/15
  • Rating change
    Stifel Maintains Global Partners(GLP.US) With Hold Rating, Cuts Target Price to $45
    Market Newswire · 2025/11/11
  • Rating change
    Raymond James Initiates Global Partners(GLP.US) With Hold Rating
    Market Newswire · 2026/8/11
  • Company notice
    ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS' ORAL SMALL MOLECULE GLP-1, ASC30, DEMONSTRATEDPLACEBO-ADJUSTED HBA1C REDUCTION OF 1.7% AT 12 WEEKS FROMITS U.S. PHASE II STUDY IN PARTICIPANTS WITH DIABETES
    HKEX · 2026/10/29
  • Rating change
    Morgan Stanley: Hims' Target Price is $40 with an 18% downside potential, and the GLP-1 lawsuit tug-of-war is the biggest variable.
    Zhitong Finance · 2025/7/9
  • Rating change
    TR | OpenAI - 4o Downgrades Global Partners(GLP.US) to Hold Rating, Cuts Target Price to $57
    Market Newswire · 2025/8/6
  • Rating change
    Yinuos (688710): Nantong Yinuos' "High-Quality Non-Clinical Innovative Drug Comprehensive Evaluation Platform Expansion Project" has obtained NMPA GLP certification.
    Northeast Securities · 2026/6/11
  • Company notice
    ASCLETIS-B: VOLUNTARY ANNOUNCEMENT -ASCLETIS SUBMITS IND APPLICATION TO THE U.S. FDA FOR ASC30_39FDC, A POTENTIALLY FIRST-IN-CLASS ORAL SMALL MOLECULEFIXED-DOSE COMBINATION OF GLP-1R AGONIST AND SELECTIVEAMYLIN RECEPTOR AGONIST, FOR THE TREATMENT OF OBESITY
    HKEX · 2026/11/11
  • Rating change
    CLSA: Upgrades Fosun Pharma (02196) target price to HKD 31.6 following GLP-1 drug collaboration with Pfizer (PFE.US).
    Zhitong Finance · 2025/12/10
  • Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity
    PR Newswire · 2026/11/11
  • Rating change
    Stifel Maintains Global Partners(GLP.US) With Hold Rating, Maintains Target Price $53
    Market Newswire · 2025/8/13
  • Hims & Hers Struck a GLP-1 Deal With Lilly. Its Stock Is Rallying.
    MarketWatch · 2026/11/7
  • Rating change
    GLP-1 drugs reshape consumer habits, and Wall Street rarely lowers McDonald's rating.
    wallstreetcn · 2025/6/10
  • Company notice
    ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. FDA IND CLEARANCE FOR PHASE I STUDYOF ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR DUAL PEPTIDE AGONIST, ASC35, FOR THE TREATMENT OF OBESITY
    HKEX · 2026/6/23
  • Big Pharma's Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)
    TipRanks · 2026/10/22
  • Ascletis Pharma-B (01672.HK): In the U.S. Phase II study of ASC30, an oral small-molecule GLP-1 agent, among subjects with diabetes, placebo-adjusted glycated hemoglobin (HbA1c) reduction reached 1.7% at Week 12.
    Gelonghui Finance · 2026/10/29
  • Eli Lilly and Co. reported a 39% year-over-year increase in Q3 revenue, significantly exceeding expectations, with GLP-1 accounting for over 60% of its revenue, and raised its full-year guidance for the third time this year.
    wallstreetcn · 2026/10/29
  • Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks From Its U.S. Phase II Study in Participants With Diabetes
    PR Newswire · 2026/10/29

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Global Partners discussion 0 comments

Add a comment